Abstract: Cervical cancer patients who develop distant metastasis are rarely curable with very limited treatment options. Chemotherapy is often administered but with limited efficacy. Immunotherapy and anti-angiogenesis therapy are recommended for selected cases of recurrent or metastatic cervical cancers. The clinical efficacy of inhibitors targeting HER2, a commonly mutated gene in cervical cancer, has not been elucidated. Herein, we report a metastatic cervical adenocarcinoma patient carrying HER2 G292R who benefited from pyrotinib after progression on radio-chemotherapy, achieving complete response (CR) with a progression-free survival of 25 months and counting. Our study sheds light on the treatment options for previously treated metastatic cervical adenocarcinoma patients harboring activating HER2 mutations.

Keywords: cervical cancer, adenocarcinoma, HER2, pyrotinib, complete response


中文翻译：

---

携带 HER2 G292R 的转移性宫颈腺癌患者在吡罗替尼治疗后获得完全缓解

摘要：发生远处转移的宫颈癌患者很少能通过非常有限的治疗选择治愈。经常进行化疗，但疗效有限。对于特定的复发或转移性宫颈癌病例，推荐免疫疗法和抗血管生成疗法。HER2是宫颈癌中常见的突变基因，其抑制剂的临床疗效尚未阐明。在此，我们报告了一名携带HER2的转移性宫颈腺癌患者G292R 在放化疗进展后从吡罗替尼中获益，实现完全缓解 (CR)，无进展生存期为 25 个月，并在计算中。我们的研究阐明了先前治疗过的携带激活性HER2 突变的转移性宫颈腺癌患者的治疗选择。

关键词：宫颈癌，腺癌，HER2，吡罗替尼，完全缓解